Empirical Characteristics of Litigation Involving Tissue Plasminogen Activator and Ischemic Stroke
- 31 August 2008
- journal article
- Published by Elsevier BV in Annals of Emergency Medicine
- Vol. 52 (2), 160-164
- https://doi.org/10.1016/j.annemergmed.2007.12.017
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Thrombolytic Therapy for Acute Ischemic StrokeStroke, 2007
- Stroke and the Emergency PhysicianEmergency Medicine News, 2007
- Will EPsʼ Reluctance to Embrace Thrombolysis for Stroke Lead to Lawsuits?Emergency Medicine News, 2006
- Thrombolysis (Tissue Plasminogen Activator) in StrokeStroke, 2006
- Will EPsʼ Reluctance to Embrace Thrombolysis for Stroke Lead to Lawsuits?Emergency Medicine News, 2006
- Reasons Why Few Patients With Acute Stroke Receive Tissue Plasminogen ActivatorArchives of Neurology, 2006
- Survey of Emergency Physicians About Recombinant Tissue Plasminogen Activator for Acute Ischemic StrokeAnnals of Emergency Medicine, 2005
- Eligibility for Recombinant Tissue Plasminogen Activator in Acute Ischemic StrokeStroke, 2004
- Layperson and physician perceptions of the malpractice system: implications for patient safetySocial Science & Medicine, 2002